BTG2

Across TCGA pan-cancer cohorts, BTG2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated BTG2 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BTG2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated BTG2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD and LSCC are the cancer types where BTG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	0.816	0.391	.017	4	view →
LSCC	DFS	Median	All	0.854	0.671	.019	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

BTG2–LUAD (OS)

Open the LUAD breakdown →